La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.

Pmb cdl conditions

CDL Condition
Clinical Entry Criteria / Information required
• Dx required by specialist physician, paediatrician or endocrinologist, or state hospital provider • All other disciplines, to submit pathology confirming the diagnosis • Spirometric demonstration of at least partially reversible airflow obstruction (adults and children > 5 years) • Changes in peakflow in response to a B2-agonist • Diagnosis to be confirmed by a psychiatrist • the primary psychiatric diagnosis/condition • co-morbid psychiatric conditions contributing • any other medically contributing conditions • Psycho-social (e.g. drug and alcohol abuse, environmental factors etc.) • Anti-microbial agents subject to culture and sensitivity/ antibiograms, excluding macrolides which are added as part of treatment of • NYHA stage (if available) and/or Ejection Fraction (echocardiogram results) • Sub-type must be specified - Dilated Congestive, Hypertrophic or Restrictive type • NYHA stage (if available) and/or Ejection Fraction (echocardiogram results) • Spirometric tests results - GOLD guidelines applied • Clinical risk profile (e.g. smoking and exacerbation history) • Antibiogram for non-first line antibiotics or history of use CDL Condition
Clinical Entry Criteria / Information required
• ICD-10 code and specialist physician (or nephrologist) Rx required • submit FBC and phosphate levels for consideration for EPO *If the patient's age, body weight and serum creatinine are known, the creatinine clearance can be calculated as follows: Clcreat = (140 - age [yr]) x body wt [kg]) • Angina pectoris with supportive findings on ECG (exercise or stress), Duke Treadmill test, echocardiography or angiography • Evidence of Acute Coronary Syndrome (date and type of event: acute MI, subsequent MI, coronary angioplasty, unstable angina, stent insertion, • Lipogram or Total choloesterol (not finger prick blood test) • Dx required by specialist physician, paediatrician, surgeon, gastroenterologist, or state hospital provider • Dx required by specialist physician, paediatrician, neurosurgeon, neurologist, endocrinologist, or state hospital • If age of onset is <16 y and insulin only - Dx accepted from Dr or pharmacy • If age of onset is ≥ 16y - in both symptomatic and asymptomatic patients the diagnosis is based on the following • plasma venous blood values (not fingerprick) values: • Random blood glucose, fasting blood glucose at initiation; HbA1c needed six(6) monthly thereafter • Patient must need insulin only (not on oral treatment at all) • If patient starts with a sulphonylurea (SU) only - Dx accepted from Dr or pharmacy • If patient starts with metformin (MET), glitazone (TZD), gliptin (DPP4-I) or any other Tx* - in both symptomatic and asymtomatic patients the diagnosis is based on the following plasma venous blood (not fingerprick) values: • Random blood glucose, fasting blood glucose at initiation; HbA1c needed six(6) monthly thereafter • In cases where the patient is already on therapy (and hence RBG or FBG not available), due to diagnosis long ago, the HbA1c may be accepted for * To exclude cases where these drugs are used for glucose intolerance, metabolic syndrome, insulin resistance or PCOD, but patient does not have • ECG results to be submitted by the treating doctor CDL Condition
Clinical Entry Criteria / Information required
• Complete clinical history of the seizures; EEG tests results if available or where clinical history is not clear • If history of Bipolar, Schizophrenia, Depression, Neuropathy or Migraine authorisations and/or claims for drugs for these conditions: EEG/specialist report, or neurologist to confirm Dx telephonically • Laboratory report showing Factor VIII and IX levels • Haematologist, physician's or state hospital Rx required • The South African Antiretroviral Treatment Guidelines 2013, Version 14 March 2013, apply • Details of any symptomatic atherosclerotic disease and CV events, such as: • Occlusion/stenosis of peripheral arteries; severity classification of PAD • Blood pressure readings: at least 2 readings on different dates (at least 3/12 apart), unless BP is >180/110 or patient is at very high risk (see 3rd bullet), in which case one BP reading is sufficient • Clinical risk profile (information on associated CV conditions such as CAD, Diabetes, Heart failure, CKD, Stroke, PVD, Retinopathy, Chronic Kidney Disease - if patient is not yet registered for one or more of these) • Baseline (pre-treatment) lab report with TSH value required – patient only to be registered if TSH is above upper limit of normal (may vary from • If patient is ≤ 50 years – Lab report showing LH, FSH, Oestradiol-17β and progesterone levels • Dx required by specialist physician, neurologist, or state hospital provider • EDSS and subtype of disease to be specified • Dx required by specialist physician, neurologist, or state hospital provider • The initial diagnosis may be confirmed by any registered doctor • Access to second and third level items will require intervention by a neurologist or physician CDL Condition
Clinical Entry Criteria / Information required
• If no DMARDs: The initial diagnosis may be confirmed by any registered doctor, provided that the diagnosis is confirmed with diagnostic proof • Access to second and third level items will require intervention by a specialist physician, paediatrician or a rheumatologist • Dx required by psychiatrist, paediatric psychiatrist, or state hospital provider • Dx required by specialist physician, paediatrician, rheumatologist, or state hospital provider • Dx required by specialist physician, surgeon, gastroenterologist, or state hospital provider Additional Chronic
Clinical Entry Criteria / Information required
Conditions
• Only funded on selective options from the chronic benefit • Two reports from 2 independent clinicians, one of whom must be a child psychiatrist • A teacher's report as well as the child psychiatrist report will be acceptable • Only funded on selective options from the chronic benefit • The diagnosis must clearly state all of the following: • The primary psychiatric diagnosis/condition • Co-morbid psychiatric conditions contributing • Any other medically contributing conditions • Pscyho-social (e.g. drug and alcohol abuse, environmental factors etc.) • Additional clinical information required: • HAM-D score must be submitted at initial diagnosis and thereafter on six(6) monthly follow up consultations • Requests for continuation of second and third line therapy must be accompanied by HAM-D score every 3 to 6 months thereafter • Only funded on selective options from the chronic benefit • The diagnosis must be confirmed by a neurologist.
• Only funded on selective options from the chronic benefit • The diagnosis must be confirmed by a dermatologist

Source: http://www.resomed.co.za/links/PMB%20CDL%20Conditions.pdf